AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$AZN

Sharma Mani purchased $3K of AZN

Sharma Mani (See Remarks) purchased 20 shares of ASTRAZENECA PLC (AZN) at $160.57 on 2026-08-08.

Original reporting
SEC EDGAR · Sharma Mani
Published Sep 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AZN
Neutral
low confidence
Mentioned
$AZN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AZNNeutralLow
01

Why it matters

The disclosed purchase is minor and unlikely to move the stock, but it confirms insider activity.

02

Market read

Low relevance; a routine insider purchase with minimal market impact.

03

What to watch

Insider may be accumulating for a future larger purchase; monitor subsequent filings.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions; required to be reported promptly.

Company-level read

Ticker impact

$AZNNeutralLow confidence
Context

Officer Sharma Mani purchased 20 shares of AstraZeneca at $160.57 each, total $3.25K, filing on 2026-09-11.

Expected impact

minimal, no immediate move expected

Evidence & confidence

Purchase size is tiny relative to market cap; insider is not a major holder change.

Market effects

Sector

None; AstraZeneca operates in pharma sector with no broader effect from this tiny trade.

Regional

None; transaction is US‑listed ADR, no regional ripple.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; could be a subtle bullish cue.

Key entities

  • Company
    AstraZeneca PLC

    Global pharmaceutical company, ticker AZN.

  • Officer
    Sharma Mani

    Insider reporting the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AZN insider trading history →

Related articles

OCT 15
$AZNMed

AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billion

AstraZeneca and insitro have partnered to use AI for drug discovery, focusing on metabolic dysfunction-associated steatohepatitis and cardiomyopathies. insitro will receive $40 million upfront and up to $1.46 billion in milestones. AstraZeneca gains exclusive rights to advance selected programs. The collaboration aims to accelerate drug development using insitro's AI platform and AstraZeneca's clinical expertise.

pulse2.com3 min
OCT 15
$AZNMed

AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion

AstraZeneca and insitro have agreed to collaborate on drug discovery using AI to target metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will receive $40 million upfront and up to $1.46 billion in milestones. AstraZeneca will lead development and commercialization, with exclusive worldwide rights to the programs. The collaboration aims to leverage insitro's AI platform for identifying disease drivers and novel targets.

pharmexec.com6 min
OCT 15
$AZNMed

Insitro, AstraZeneca Sign AI Drug Discovery Deal

Insitro and AstraZeneca (AZN) have partnered to use AI for drug discovery in MASH and cardiomyopathies. Insitro receives $40M upfront, with up to $1.46B in milestones and royalties. AZN stock rose 3.99% Wednesday, and is up 2.82% in pre-market trading.

rttnews.com1 min